| Drug Name |
Prochlorperazine maleate |
| Drug ID |
BADD_D01850 |
| Description |
Prochlorperazine, also known as compazine, is a piperazine phenothiazine and first-generation antipsychotic drug that is used for the treatment of severe nausea and vomiting, as well as short-term management of psychotic disorders such as generalized non-psychotic anxiety and schizophrenia.[label] It mainly works by depressing the chemoreceptor trigger zone and blocking D2 dopamine receptors in the brain. It was shown to also block histaminergic, cholinergic and noradrenergic receptors.[L6637] Prochlorperazine was first developed in the 1950s [L6643] and was first approved by the FDA in 1956. Although newer antiemetic agents such as 5-HT3 antagonists are more heavily promoted, prochlorperazine is still widely used in nausea and vomiting.[L6640] |
| Indications and Usage |
For the symptomatic management of psychotic disorders, short term management of nonpsychotic anxiety in patients with generalized anxiety disorder, and for the control of severe nausea and vomiting of various causes. |
| Marketing Status |
Prescription; Discontinued |
| ATC Code |
N05AB04 |
| DrugBank ID |
DB00433
|
| KEGG ID |
D00479
|
| MeSH ID |
D011346
|
| PubChem ID |
5281032
|
| TTD Drug ID |
D0B2UZ
|
| NDC Product Code |
50268-685; 43063-353; 63187-877; 67296-0727; 70518-1620; 38779-0180; 63187-502; 59746-115; 66267-826; 50090-0110; 50090-2242; 42291-729; 50268-684; 68788-7628; 55289-224; 42291-728; 55154-4342; 63629-1841; 63187-251; 0378-5105; 0378-5110; 61919-653; 50090-1854; 71335-0543; 50090-2839; 59746-113; 50090-2241; 71335-0952; 67296-0238; 46204-0106; 61919-908; 42708-103; 66267-271; 43063-742; 69575-4020 |
| Synonyms |
Prochlorperazine | Prochlorperazine Edisylate Salt | Edisylate Salt, Prochlorperazine | Salt, Prochlorperazine Edisylate | Prochlorperazine Edisylate | Edisylate, Prochlorperazine | Prochlorperazine Maleate | Maleate, Prochlorperazine | Compazine |
